Adherence to oral anticoagulant therapy in secondary XXXX prevention - impact of the novel oral anticoagulants.

@entity1 @entity64 @entity1697 @entity2067 @entity63 @entity3926 @entity955 @entity385
BACKGROUND: @entity1697 ( @entity1697 ) potently prevents @entity64 in @entity1 with @entity955 . @entity2067 antagonists (VKA) have been the standard of care for long-term @entity1697 for decades, but non-VKA oral anticoagulants (NOAC) have recently been approved for this indication, and raised many questions, among them their influence on medication adherence. We assessed adherence to VKA and NOAC in secondary @entity64 prevention. METHODS: All @entity1 treated from October 2011 to September 2012 for @entity385 or transient @entity63 attack with a subsequent indication for @entity1697 , at three academic hospitals were entered into a prospective registry, and baseline data and antithrombotic treatment at discharge were recorded. At the 1-year follow-up, we assessed the adherence to different @entity1697 strategies and @entity1 ' adherence to their respective @entity1697 . We noted @entity1697 changes, reasons to change treatment, and factors that influence persistence to the prescribed @entity1697 . RESULTS: In @entity1 discharged on @entity1697 , we achieved a fatality corrected response rate of 73.3% (n=209). A total of 92% of these @entity1 received @entity1697 at the 1-year follow-up. We observed good adherence to both VKA and NOAC (VKA, 80.9%; NOAC, 74.8%; P=0.243) with a statistically nonsignificant tendency toward a weaker adherence to @entity3926 . Disability at 1-year follow-up was an independent predictor of lower adherence to any @entity1697 after multivariate analysis, whereas the choice of @entity1697 did not have a relevant influence. CONCLUSION: One-year adherence to @entity1697 after @entity64 is strong (>90%) and @entity1 who switch therapy most commonly switch toward another @entity1697 . The 1-year adherence rates to VKA and NOAC in secondary @entity64 prevention do not differ significantly between both therapeutic strategies.
